Precision BioSciences Reports Positive Safety Review for PBGENE-DMD Trial
The first patient completed the post-treatment observation period with no reported safety issues, supporting additional dosing in the Phase 1/2 FUNCTION-DMD study.
The first patient completed the post-treatment observation period with no reported safety issues, supporting additional dosing in the Phase 1/2 FUNCTION-DMD study.